Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

{"title":"Re: «Evaluación del papel de la sarcopenia y los parámetros [18F]FDG PET/TC en el pronóstico del adenocarcinoma ductal pancreático»","authors":"D. Mut Surmeli","doi":"10.1016/j.remn.2025.500125","DOIUrl":"10.1016/j.remn.2025.500125","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500125"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II","authors":"L. Sancho ,&nbsp;A. Roteta ,&nbsp;I. Torres ,&nbsp;M. de Arcocha ,&nbsp;R. Ramos ,&nbsp;M.L. Domínguez ,&nbsp;J.J. Rosales ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;en nombre del Grupo de Oncología de la SEMNim","doi":"10.1016/j.remn.2025.500128","DOIUrl":"10.1016/j.remn.2025.500128","url":null,"abstract":"<div><div>The state of the art and future perspectives of new radionuclides in Nuclear Medicine continue to evolve, driven by the development of isotopes with innovative applications in theragnostics.</div><div>In this second part of the continuing education series, the clinical and therapeutic applications of terbium, actinium, and bismuth are analyzed in depth. The use of the 4<!--> <!-->terbium isotopes (terbium-149, terbium-152, terbium-155, and terbium-161) is described, offering a versatile system for both diagnosis and treatment due to their chemical similarity to lutetium-177, along with the challenges related to their production and availability. Additionally, actinium-225, a powerful alpha-emitting radionuclide, is reviewed for its growing role in targeted alpha therapy, particularly in prostate cancer and neuroendocrine tumors. Finally, bismuth-213, derived from actinium-225, is analyzed for its short half-life, making it a viable option for localized and selective therapies.</div><div>Despite technical and production challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities in Nuclear Medicine.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500128"},"PeriodicalIF":1.6,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilidad del [18F]FDG PET/TC en el manejo del linfoma óseo primario","authors":"M. Mangas Losada ,&nbsp;I. Garcia Megías ,&nbsp;R. Mangas Losada ,&nbsp;L.G. Romero Robles ,&nbsp;X. Boulvard Chollet ,&nbsp;R. Ramírez Lasanta","doi":"10.1016/j.remn.2025.500126","DOIUrl":"10.1016/j.remn.2025.500126","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500126"},"PeriodicalIF":1.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143867270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Análisis de variables dosimétricas y clínicas en el tratamiento de los tumores neuroendocrinos con [177Lu]Lu-DOTA-TATE","authors":"P. Mínguez Gabiña ,&nbsp;T. Monserrat Fuertes ,&nbsp;B. Santos Zorrozua ,&nbsp;A. Esteban Figueruelo ,&nbsp;M.A. Astudillo Sarmiento ,&nbsp;A. Peña Fuentes ,&nbsp;I. Vinagre Pérez ,&nbsp;E. Rodeño Ortiz de Zarate ,&nbsp;I.L. Fernández Tercero","doi":"10.1016/j.remn.2024.500089","DOIUrl":"10.1016/j.remn.2024.500089","url":null,"abstract":"<div><h3>Purpose</h3><div>The main objectives were to study differences between the first and the fourth cycle in dosimetry variables in patients treated for neuroendocrine tumours with four cycles of [¹⁷⁷Lu]Lu-DOTA-TATE, as well as to look for absorbed dose–effect correlations aiming to help individualise and optimise this therapy for future patients.</div></div><div><h3>Material and methods</h3><div>SPECT based dosimetry of tumour lesions and kidneys was performed in the first and the fourth cycles of the [¹⁷⁷Lu]Lu-DOTA-TATE treatments for 17 patients from 2020 to 2023. Clinical variables of interest were collected in order to look for correlations with some dosimetry variables. Statistical analysis was performed using the R software.</div></div><div><h3>Results</h3><div>Regarding dosimetry variables, for lesions a significant decrease in absorbed dose, mass and initial activity between the first and fourth cycles was observed. For kidneys, a significant increase in absorbed dose was observed. Effective decay constants did not significantly change neither for lesions nor for kidneys. The relative decrease in lesion masses correlated with their total absorbed dose. Total absorbed doses to kidneys were well below the toxicity limits mostly used in this therapy. Relative decr</div><div>ease in lesion absorbed doses was significantly lower for tumour primary sites in ileum and jejunum compared to those in pancreas. Moreover, radiological response correlated with clinical response.</div></div><div><h3>Conclusions</h3><div>The results seem to indicate that the current treatment scheme could be optimised in order to obtain better treatment outcomes.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500089"},"PeriodicalIF":1.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre los hallazgos de la PET/TC con [18F]FDG y los subtipos histológicos de adenocarcinoma de pulmón que se presentan como opacidad en vidrio deslustrado","authors":"H. Ji ,&nbsp;S. Jiang ,&nbsp;C. Sun ,&nbsp;T. Liu ,&nbsp;G. Yang ,&nbsp;L. Zhang ,&nbsp;J. Sun ,&nbsp;J. Wu","doi":"10.1016/j.remn.2024.500087","DOIUrl":"10.1016/j.remn.2024.500087","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study is to analyze the correlation between [18F]-FDG PET/CT (positron emission tomography/computed tomography) findings and pathological subtypes of lung adenocarcinoma with ground-glass opacity (GGO).</div></div><div><h3>Materials and methods</h3><div>88 patients were included in this study, which underwent [18F]-FDG PET/CT and were finally diagnosed with lung adenocarcinoma. A total of 90 GGO lesions were analyzed. The size and SUV_max of all lesions were measured, the proportion of solid components of GGO in lesions was calculated, and quantitative classification was performed. The above GGO lesions were divided into three groups based on the 2011 IASLC/ATS/ERS lung adenocarcinoma pathological classification, namely good prognosis group, relatively good prognosis group and poor prognosis group. Chi-square test, independent sample t test, and analysis of variance were used for statistical analysis.</div></div><div><h3>Results</h3><div>There was a negative correlation between the SUV_max and quantitative classification value (<em>r</em> =−0.638, <em>P</em> &lt; 0.001). Atypical adenomatous hyperplasia (AAH), acinar predominant adenocarcinoma (APA), lepidic predominant adenocarcinoma (LPA), papillary predominant adenocarcinoma (PPA), and solid pre-dominant adenocarcinoma (SPA) had significant differences in GGO lesion size, SUV_max, and quantitative classification value (<em>F</em> = 3.849, <em>P</em> = 0.019; <em>F</em> = 27.420, <em>P</em> &lt; 0.001; <em>F</em> = 4.353, <em>P</em> = 0.002). There were significant differences in GGO lesion size, SUV_max, and quantitative classification value among the good prognosis group, relatively good prognosis group, and poor prognosis group (<em>F</em> = 5.626, <em>P</em> = 0.011; <em>F</em> = 37.587, <em>P</em> &lt; 0.001; <em>F</em> = 5.119, <em>P</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>GGO lesion size, SUV_max, and quantitative classification value are correlated with different pathological subtypes and can be used to evaluate the prognosis of lung adenocarcinoma with GGO.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500087"},"PeriodicalIF":1.6,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malacoplaquia renal y pulmonar con afectación mediastínica que simula en estudio PET/TC con [18F]FDG una neoplasia sincrónica","authors":"J.R. Garcia,&nbsp;A. Compte,&nbsp;S. Romero,&nbsp;L. Mont,&nbsp;L. Pinilla,&nbsp;E. Riera","doi":"10.1016/j.remn.2025.500124","DOIUrl":"10.1016/j.remn.2025.500124","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500124"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas","authors":"K.-H. Lin ,&nbsp;J.-C. Wu ,&nbsp;M.-C. Wu","doi":"10.1016/j.remn.2024.500056","DOIUrl":"10.1016/j.remn.2024.500056","url":null,"abstract":"<div><h3>Objective</h3><div>The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome, and determine the incidence and onset time of hypothyroidism following low-dose RAI.</div></div><div><h3>Material and methods</h3><div>A total of 158 patients who received doses less than 370<!--> <!-->Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs. 113 female), age (77 patients ≥<!--> <!-->45<!--> <!-->years old vs. 81 patients &lt;<!--> <!-->45<!--> <!-->years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222<!--> <!-->MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.</div></div><div><h3>Results</h3><div>Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, <em>P</em> <!-->=<!--> <!-->.260) and hypothyroidism incidences (26.9% vs. 38.5%, <em>P</em> <!-->=<!--> <!-->.170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (<em>P</em> <!-->=<!--> <!-->.69 in response rates and <em>P</em> <!-->=<!--> <!-->.75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, <em>P</em> <!-->=<!--> <!-->.008) and hypothyroidism incidence (46.3% vs. 13.3%, <em>P</em> <!-->=<!--> <!-->.004) compared to males. Hypothyroidism onset occurred at a mean of 24.0<!--> <!-->±<!--> <!-->29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.</div></div><div><h3>Conclusions</h3><div>Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500056"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valor de la PET/TC con [18F]FDG en el diagnóstico y grado histopatológico de los adenomas colorrectales incidentales","authors":"Z. Qi ,&nbsp;K. Tang ,&nbsp;X. Lu ,&nbsp;Y. Zhu ,&nbsp;N. Xu","doi":"10.1016/j.remn.2024.500075","DOIUrl":"10.1016/j.remn.2024.500075","url":null,"abstract":"<div><h3>Purpose</h3><div>Colorectal adenomas (CRAs) are at a higher risk of progressing to colorectal cancer (CRC) as their histological grade increases. Herein, this study investigated the relationship between the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([¹⁸F]FDG PET/CT) and the histological grades of CRAs and constructed the optimal regression model for distinguishing between different histological grades.</div></div><div><h3>Methods</h3><div>This study retrospectively analyzed the data of 153 patients with CRAs who had colorectal [¹⁸F]FDG uptake incidentally found on PET/CT. The patients were categorized into low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN) groups based on their histological grade. After the analysis of the relationship between SUVmax measured on preoperative [¹⁸F]FDG PET/CT scans and histological grades, receiver-operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for distinguishing between the two groups. Common clinical and pathological factors were included and subjected to univariate and multivariate logistic regression analyses to identify independent risk factors. A diagnostic model integrating SUVmax and several risk factors was developed with the multivariate logistic regression analysis.</div></div><div><h3>Results</h3><div>SUVmax was significantly different between the two groups (<em>P</em> <!-->&lt;<!--> <!-->.001) and increased with an elevation in the malignancy degree. The area under the ROC curve (AUC) for identifying LGIN and HGIN was 0.796, and the AUC of the combination model was 0.822. Furthermore, SUVmax was an independent risk factor for distinguishing between different histological grades in pairwise comparisons.</div></div><div><h3>Conclusion</h3><div>The regression model involving SUVmax on [¹⁸F]FDG PET/CT can distinguish between histological grades of CRAs, which therefore can be used as a noninvasive tool for the accurate diagnosis of CRAs and assist in developing patient-specific treatment strategies before surgery.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500075"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparación de la estadificación mediante [68Ga]Ga-PSMA-11 PET/TC y los resultados anatomopatológicos en pacientes con cáncer de próstata de riesgo intermedio y alto tratados con prostatectomía radical y linfadenectomía pélvica","authors":"J.J. Rosales ,&nbsp;V. Betech Antar ,&nbsp;F. Mínguez ,&nbsp;F. Pareja ,&nbsp;F. Guillén ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;F. Díez Caballero ,&nbsp;B. Miñana ,&nbsp;J.L. Pérez-Gracia ,&nbsp;M. Rodríguez-Fraile","doi":"10.1016/j.remn.2024.500076","DOIUrl":"10.1016/j.remn.2024.500076","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-PSMA-11 PET/CT (PET-PSMA) in local and loco-regional nodal staging compared with histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND).</div></div><div><h3>Materials y methods</h3><div>A total of 122 intermediate- and high-risk prostate cancer (PCa) patients staged with PET-PSMA and treated with RP (36/122) and RP plus PLND (86/122) from December 2018 to December 2023 were included. Visual and semiquantitative analysis findings using the SUVmax of the molecular imaging were correlated with histopathological results.</div></div><div><h3>Results</h3><div>The primary tumor was visible by PET-PSMA in 96.7% of the patients. A positive correlation was found between PSA levels and SUVmax (Spearman's r: 0.303, p&lt;<!--> <!-->0.001). PET-PSMA detected nodal involvement in 25/89 patients (28.08%). The sensitivity, specificity, and diagnostic accuracy of PET-PSMA for detecting nodal involvement were 75%, 82.2%, and 80.9%, respectively. Patients with PSA levels<!--> <!-->&gt;20 ng/ml, Gleason score ≥7b, ISUP grade<!--> <!-->&gt;2, and extracapsular extension showed significantly higher SUVmax values. No differences were observed in SUVmax between risk groups or in other histopathological variables.</div></div><div><h3>Conclusions</h3><div>PET-PSMA is an effective tool for the initial staging of intermediate- and high-risk PCa. SUVmax values were significantly higher in patients with unfavorable clinical features.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500076"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Falsa imagen de recidiva ganglionar en la PET/TC con [68Ga]Ga-PSMA-11. Importancia del protocolo de adquisición","authors":"C. Castillo-Arias ,&nbsp;D. Vas ,&nbsp;E. García ,&nbsp;K. Quintero ,&nbsp;M. Tormo ,&nbsp;P. Paredes","doi":"10.1016/j.remn.2024.500077","DOIUrl":"10.1016/j.remn.2024.500077","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500077"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}